JP6846931B2 - 高脂血症を処置するためのｐｃｓｋ９阻害剤の使用 - Google Patents

高脂血症を処置するためのｐｃｓｋ９阻害剤の使用 Download PDF

Info

Publication number
JP6846931B2
JP6846931B2 JP2016521604A JP2016521604A JP6846931B2 JP 6846931 B2 JP6846931 B2 JP 6846931B2 JP 2016521604 A JP2016521604 A JP 2016521604A JP 2016521604 A JP2016521604 A JP 2016521604A JP 6846931 B2 JP6846931 B2 JP 6846931B2
Authority
JP
Japan
Prior art keywords
patients
patient
ldl
antibody
week
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016521604A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016538248A5 (enExample
JP2016538248A (ja
Inventor
マリー・バカラ−ディネット
ロランス・ベサック
ウーメッシュ・シャウダーリ
コリンヌ・アノトン
ロバート・シー・ポーディー
ウィリアム・ジェイ・サシーラ
ダニエル・エー・シュヴェンマー・ジャイプ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of JP2016538248A publication Critical patent/JP2016538248A/ja
Publication of JP2016538248A5 publication Critical patent/JP2016538248A5/ja
Application granted granted Critical
Publication of JP6846931B2 publication Critical patent/JP6846931B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Emergency Medicine (AREA)
JP2016521604A 2013-10-11 2014-10-10 高脂血症を処置するためのｐｃｓｋ９阻害剤の使用 Active JP6846931B2 (ja)

Applications Claiming Priority (17)

Application Number Priority Date Filing Date Title
US201361890154P 2013-10-11 2013-10-11
US61/890,154 2013-10-11
US201461923103P 2014-01-02 2014-01-02
US61/923,103 2014-01-02
US201461955514P 2014-03-19 2014-03-19
US61/955,514 2014-03-19
US201462004620P 2014-05-29 2014-05-29
US62/004,620 2014-05-29
US201462025104P 2014-07-16 2014-07-16
US62/025,104 2014-07-16
EP14306221.4 2014-07-31
EP14306221 2014-07-31
US201462054571P 2014-09-24 2014-09-24
US62/054,571 2014-09-24
EP14306584.5 2014-10-09
EP14306584 2014-10-09
PCT/US2014/060109 WO2015054619A2 (en) 2013-10-11 2014-10-10 Use of a pcsk9 inhibitor to treat hyperlipidemia

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019146940A Division JP6994484B2 (ja) 2013-10-11 2019-08-09 高脂血症を処置するためのｐｃｓｋ９阻害剤の使用

Publications (3)

Publication Number Publication Date
JP2016538248A JP2016538248A (ja) 2016-12-08
JP2016538248A5 JP2016538248A5 (enExample) 2017-11-16
JP6846931B2 true JP6846931B2 (ja) 2021-03-24

Family

ID=52813751

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016521604A Active JP6846931B2 (ja) 2013-10-11 2014-10-10 高脂血症を処置するためのｐｃｓｋ９阻害剤の使用
JP2019146940A Active JP6994484B2 (ja) 2013-10-11 2019-08-09 高脂血症を処置するためのｐｃｓｋ９阻害剤の使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019146940A Active JP6994484B2 (ja) 2013-10-11 2019-08-09 高脂血症を処置するためのｐｃｓｋ９阻害剤の使用

Country Status (14)

Country Link
US (1) US20150140002A1 (enExample)
EP (2) EP3689913B1 (enExample)
JP (2) JP6846931B2 (enExample)
KR (3) KR20160062166A (enExample)
CN (3) CN115154599A (enExample)
AU (2) AU2014331754B2 (enExample)
CA (1) CA2926942A1 (enExample)
EA (1) EA037526B1 (enExample)
ES (1) ES2914978T3 (enExample)
IL (1) IL244995B (enExample)
MX (3) MX373298B (enExample)
PL (2) PL3055333T4 (enExample)
TW (1) TWI669131B (enExample)
WO (1) WO2015054619A2 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
US20130064834A1 (en) 2008-12-15 2013-03-14 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to pcsk9
MX347602B (es) 2011-01-28 2017-05-03 Sanofi Biotechnology Composiciones farmaceuticas que comprenden anticuerpos humanos frente a pcsk9.
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
PL4252857T3 (pl) 2011-09-16 2025-03-03 Regeneron Pharmaceuticals, Inc. Sposoby redukowania poziomów lipoproteiny(a) poprzez podawanie inhibitora proproteinowej konwertazy subtylizyny keksyny-9 (pcsk9)
US9255154B2 (en) 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
US10058630B2 (en) * 2012-10-22 2018-08-28 Concievalve, Llc Methods for inhibiting stenosis, obstruction, or calcification of a stented heart valve or bioprosthesis
US10111953B2 (en) 2013-05-30 2018-10-30 Regeneron Pharmaceuticals, Inc. Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
CA2914721A1 (en) 2013-06-07 2014-12-11 Regeneron Pharmaceuticals, Inc. Methods for inhibiting atherosclerosis by administering an inhibitor of pcsk9
JP6616298B2 (ja) 2013-11-12 2019-12-04 サノフィ・バイオテクノロジー Ｐｃｓｋ９阻害剤と共に使用するための投薬レジメン
WO2016010927A1 (en) * 2014-07-14 2016-01-21 Amgen Inc. Crystalline antibody formulations
CA2955294A1 (en) 2014-07-16 2016-01-21 Sanofi Biotechnology Methods for treating patients with heterozygous familial hypercholesterolemia (hefh)
CN107635512A (zh) * 2015-04-15 2018-01-26 康斯瓦维有限责任公司 用于抑制天然心脏瓣膜、被支撑的心脏瓣膜或生物假体的狭窄、阻塞或钙化的装置和方法
CN104861071B (zh) * 2015-04-27 2019-04-12 南京师范大学 针对pcsk9的全人源单克隆抗体的可变区基因及其应用
US10772956B2 (en) 2015-08-18 2020-09-15 Regeneron Pharmaceuticals, Inc. Methods for reducing or eliminating the need for lipoprotein apheresis in patients with hyperlipidemia by administering alirocumab
KR20190049866A (ko) 2016-09-20 2019-05-09 우시 바이올로직스 아일랜드 리미티드 신규한 항-ｐｃｓｋ９ 항체
CA3058567A1 (en) 2017-04-13 2018-10-18 Cadila Healthcare Limited Novel peptide based pcsk9 vaccine
US20200131576A1 (en) 2017-04-25 2020-04-30 The Brigham And Women's Hospital, Inc. IL-8, IL-6, IL-1 Beta and TET2 and DNMT3A in Atherosclerosis
CN107090474A (zh) * 2017-05-22 2017-08-25 山东大学 一种腹主动脉瘤疾病动物模型的制备方法
CN109963877B (zh) * 2017-06-14 2023-01-20 江苏恒瑞医药股份有限公司 Pcsk9抗体、其抗原结合片段及其医药用途
AU2019231703A1 (en) * 2018-03-06 2020-10-22 Regeneron Pharmaceuticals, Inc. Use of PCSK9 inhibitor for reducing cardiovascular risk
JOP20190150A1 (ar) 2018-06-21 2019-12-21 Merck Sharp & Dohme مركبات مناهضة لـ pcsk9
CR20210441A (es) 2019-01-18 2022-03-11 Astrazeneca Ab Inhibidores de la pcsk9 y métodos de uso de los mismos
AU2020388182A1 (en) * 2019-11-18 2022-06-02 Ad Pharmaceuticals Co., Ltd. Anti-PCSK9 antibody and use thereof
EP4072672A1 (en) * 2019-12-10 2022-10-19 Regeneron Pharmaceuticals, Inc. Use of a pcsk9 inhibitor to treat homozygous familial hypercholesterolemia
CN114277032A (zh) * 2021-12-31 2022-04-05 华中科技大学同济医学院附属协和医院 一种低密度脂蛋白受体基因突变体及其应用
CN116983434B (zh) * 2023-09-28 2024-03-15 康霖生物科技（杭州）有限公司 用于基因治疗的核酸构建体及其用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US8357371B2 (en) * 2008-12-15 2013-01-22 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to PCSK9
US20130064834A1 (en) * 2008-12-15 2013-03-14 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to pcsk9
JO3672B1 (ar) * 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
MX347602B (es) * 2011-01-28 2017-05-03 Sanofi Biotechnology Composiciones farmaceuticas que comprenden anticuerpos humanos frente a pcsk9.
JOP20200043A1 (ar) * 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
US20130006482A1 (en) * 2011-06-30 2013-01-03 Ramadev Burigsay Hukkeri Guidance system for a mobile machine
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
PL4252857T3 (pl) * 2011-09-16 2025-03-03 Regeneron Pharmaceuticals, Inc. Sposoby redukowania poziomów lipoproteiny(a) poprzez podawanie inhibitora proproteinowej konwertazy subtylizyny keksyny-9 (pcsk9)
TWI682780B (zh) * 2013-05-30 2020-01-21 美商再生元醫藥公司 醫藥組成物用於製造治療與ｐｃｓｋ９功能獲得性突變有關之體染色體顯性高膽固醇血症的藥物之用途

Also Published As

Publication number Publication date
AU2020203636A1 (en) 2020-06-25
TW201605475A (zh) 2016-02-16
KR20230119045A (ko) 2023-08-14
KR20220048051A (ko) 2022-04-19
WO2015054619A8 (en) 2016-03-31
JP6994484B2 (ja) 2022-02-04
IL244995A0 (en) 2016-05-31
EP3055333A2 (en) 2016-08-17
CN105814085A (zh) 2016-07-27
PL3689913T3 (pl) 2022-07-04
CA2926942A1 (en) 2015-04-16
CN115192704A (zh) 2022-10-18
WO2015054619A3 (en) 2015-06-04
MX2022013172A (es) 2022-11-30
KR20160062166A (ko) 2016-06-01
IL244995B (en) 2019-12-31
AU2014331754B2 (en) 2020-06-18
US20150140002A1 (en) 2015-05-21
MX2016004580A (es) 2016-12-08
CN115154599A (zh) 2022-10-11
PL3055333T3 (pl) 2020-06-01
ES2914978T3 (es) 2022-06-20
EP3055333B1 (en) 2019-12-04
EP3689913B1 (en) 2022-03-23
EA037526B1 (ru) 2021-04-08
TWI669131B (zh) 2019-08-21
AU2020203636B2 (en) 2023-05-18
EA201690754A1 (ru) 2016-10-31
WO2015054619A2 (en) 2015-04-16
MX2020004023A (es) 2020-08-13
JP2019214594A (ja) 2019-12-19
MX373298B (es) 2020-05-20
EP3689913A1 (en) 2020-08-05
AU2014331754A1 (en) 2016-05-26
PL3055333T4 (pl) 2020-07-27
JP2016538248A (ja) 2016-12-08

Similar Documents

Publication Publication Date Title
JP6994484B2 (ja) 高脂血症を処置するためのｐｃｓｋ９阻害剤の使用
US20230406957A1 (en) Dosing regimens for use with pcsk9 inhibitors
KR20220157516A (ko) 심혈관 위험을 감소시키는 방법
JP2024016218A (ja) リポタンパク質アフェレーシスを受けている高脂血症の患者を治療するための抗ｐｃｓｋ９阻害抗体
JP2017522316A (ja) 高コレステロール血症を有する高心血管リスク患者を処置するための方法
TWI723478B (zh) Ｐｃｓｋ９抑制劑用於治療高血脂症的用途
JP2020143156A (ja) 心血管リスクを低減させる方法
JP7104108B2 (ja) ヘテロ接合性家族性高コレステロール血症（ｈｅＦＨ）を有する患者を処置するための方法
HK40033729A (en) Use of a pcsk9 inhibitor to treat hyperlipidemia
HK40033729B (en) Use of a pcsk9 inhibitor to treat hyperlipidemia
JP2020037566A (ja) Ｐｃｓｋ９阻害剤と共に使用するための投薬レジメン
HK40059806A (en) Dosing regimens for use with pcsk9 inhibitors
HK1227890A1 (en) Use of a pcsk9 inhibitor to treat hyperlipidemia
HK1227890B (en) Use of a pcsk9 inhibitor to treat hyperlipidemia

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171004

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171004

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180619

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180913

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20181114

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181219

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190409

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190809

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20190809

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20190827

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20190913

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20190917

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20191011

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20191023

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20200421

C13 Notice of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: C13

Effective date: 20200714

C28A Non-patent document cited

Free format text: JAPANESE INTERMEDIATE CODE: C2838

Effective date: 20200714

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20201006

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201013

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201113

C23 Notice of termination of proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C23

Effective date: 20210112

C03 Trial/appeal decision taken

Free format text: JAPANESE INTERMEDIATE CODE: C03

Effective date: 20210209

C30A Notification sent

Free format text: JAPANESE INTERMEDIATE CODE: C3012

Effective date: 20210209

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210302

R150 Certificate of patent or registration of utility model

Ref document number: 6846931

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250